A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin

Barriers to effective gene therapy for many diseases include the number of modified target cells required to achieve therapeutic outcomes and host immune responses to expressed therapeutic proteins. As long-lived cells specialized for protein secretion, antibody-secreting B cells are an attractive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vamva, Eirini, Ozog, Stosh, Leaman, Daniel P., Yu-Hong Cheng, Rene, Irons, Nicholas J., Ott, Andee, Stoffers, Claire, Khan, Iram, Goebrecht, Geraldine K.E., Gardner, Matthew R., Farzan, Michael, Rawlings, David J., Zwick, Michael B., James, Richard G., Torbett, Bruce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984920/
https://www.ncbi.nlm.nih.gov/pubmed/36879849
http://dx.doi.org/10.1016/j.omtm.2023.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984920/
https://www.ncbi.nlm.nih.gov/pubmed/36879849
http://dx.doi.org/10.1016/j.omtm.2023.02.004

Ejemplares similares